Stay updated on Pembrolizumab in MM Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab in MM Residual Disease Clinical Trial page
- Check2 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.8%
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.7%
- Check24 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check31 days agoNo Change Detected
- Check38 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check67 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed descriptions of a clinical trial for MK-3475 in Multiple Myeloma, while retaining the drug's name and the revision number. The focus has shifted from specific trial details to a more general mention of the drug and its context.SummaryDifference63%
Stay in the know with updates to Pembrolizumab in MM Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in MM Residual Disease Clinical Trial page.